Does Rallies show Form 4 insider transactions for PTGX?

Yes. Rallies tracks PTGX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PTGX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PTGX. It does not provide personalized investment advice.

PTGX (Protagonist Therapeutics, Inc) Stock Analysis - Insider Trades

Protagonist Therapeutics, Inc (PTGX) is a publicly traded Healthcare sector company. As of May 21, 2026, PTGX trades at $100.71 with a market cap of $6.48B and a P/E ratio of -55.44. PTGX moved +2.53% today. Year to date, PTGX is +19.84%; over the trailing twelve months it is +116.43%. Its 52-week range spans $33.31 to $107.84. Analyst consensus is strong buy with an average price target of $117.00. Rallies surfaces PTGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PTGX stock inside the company?

Recent PTGX insider activity includes PATEL DINESH V PH D sold 75.00K, PATEL DINESH V PH D sold 75.00K, Giraudo Bryan sold 6.00K, Giraudo Bryan sold 5.13K, and Giraudo Bryan sold 36.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PTGX Key Metrics

Key financial metrics for PTGX
Metric	Value
Price	$100.71
Market Cap	$6.48B
P/E Ratio	-55.44
EPS	$-1.81
Dividend Yield	0.00%
52-Week High	$107.84
52-Week Low	$33.31
Volume	295.34K
Avg Volume	0
Revenue (TTM)	$74.06M
Net Income	$-114.71M
Gross Margin	0.00%

Recent PTGX Insider Trades

PATEL DINESH V PH D sold 75.00K (~$7.51M) on May 12, 2026.
PATEL DINESH V PH D sold 75.00K (~$7.51M) on May 12, 2026.
Giraudo Bryan sold 6.00K (~$600.00K) on May 8, 2026.
Giraudo Bryan sold 5.13K (~$513.00K) on May 8, 2026.
Giraudo Bryan sold 36.00K (~$3.61M) on May 7, 2026.

Latest PTGX News

Protagonist Therapeutics jumps as Q1 profit and rusfertide Priority Review refocus attention — May 6, 2026
Protagonist Secures $200M Rusfertide Opt-Out Fee and $50M ICOTYDE Milestone — May 5, 2026
PTGX climbs as traders rotate into catalyst-driven biotech ahead of early-May results — Apr 28, 2026
Protagonist Exercises U.S. Rusfertide Opt-Out for $475M Upfront and $975M Milestones — Apr 28, 2026
PTGX slides 3% as post-rally profit-taking meets fresh insider-selling overhang — Apr 24, 2026

PTGX Analyst Consensus

11 analysts cover PTGX: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $117.00.

Common questions about PTGX

Who is trading PTGX stock inside the company?: Recent PTGX insider activity includes PATEL DINESH V PH D sold 75.00K, PATEL DINESH V PH D sold 75.00K, Giraudo Bryan sold 6.00K, Giraudo Bryan sold 5.13K, and Giraudo Bryan sold 36.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PTGX?: Yes. Rallies tracks PTGX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PTGX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PTGX. It does not provide personalized investment advice.